Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 8;1(2):558-562.
doi: 10.1002/jha2.115. eCollection 2020 Nov.

Favorable prognostic phenotype in myelodysplastic syndrome with der(1;7)(q10;p10)

Tomohiro Horio  1   2 , Megumi Enomoto  3 , Masaya Watarai  4 , Yuuta Nakano  1   2 , Saki Yamada  4 , Saori Matsumura  1   2 , Jo Kanasugi  1   2 , Soichi Takasugi  1   2 , Ayano Nakamura  1   2 , Kaori Uchino  1   2 , Shohei Mizuno  1   2 , Satsuki Murakami  1   2 , Hidesuke Yamamoto  1   2 , Ichiro Hanamura  1   2 , Akiyoshi Takami  1   2
Affiliations

Favorable prognostic phenotype in myelodysplastic syndrome with der(1;7)(q10;p10)

Tomohiro Horio et al. EJHaem. .

Abstract

Unbalanced translocation der(1;7)(q10;p10) is a characteristic chromosomal abnormality in myelodysplastic syndrome (MDS). The current study revealed that among 13 MDS patients with der(1;7)(q10;p10), seven cases with no apparent dysplasia also had low numbers of myeloblasts in the bone marrow and a 3-year survival rate of 86%; in contrast, the remaining six cases had a 3-year survival rate of 0% (P = .003). It was therefore suggested that MDS patients with der(1;7)(q10;p10) are classified into a distinct group with a favorable prognosis and another distinct group with a very poor prognosis.

Keywords: DNA mutation; MDS; cytogenetics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest in association with the present study.

Figures

FIGURE 1
FIGURE 1
A, OS in patients with der(1;7)(q10;p10). B, LT in patients with der(1;7)(q10;p10)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ganster C, Müller‐Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, et al. Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes Cancer. 2019;58:689‐97. - PubMed
    1. Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, Wang SA. Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes. Cancer. 2008;113:3331‐40. - PubMed
    1. Sanada M, Uike N, Ohyashiki K, Ozawa K, Lili W, Hangaishi A, et al. Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. Leukemia. 2007;21:992‐7. - PubMed
    1. Slovak ML, O'Donnell M, Smith DD, Gaal K. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to –7/del(7q) MDS. Cancer Genet Cytogenet. 2009;193:78‐85. - PubMed
    1. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2017.